Myeloid Leukemia News and Research

RSS

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.

Researchers test new cancer research model that may reduce cost and speed up studies

A new model for improving how clinical trials are developed and conducted by bringing together academic cancer experts and pharmaceutical companies is being tested by research experts at The University of Texas MD Anderson Cancer Center.

15 May 2018

Aravive Biologics demonstrates proof-of-mechanism for AVB-S6-500 in ongoing phase 1 study

Aravive Biologics, Inc. announced today that the company has demonstrated clinical proof-of-mechanism for AVB-S6-500 in neutralizing GAS6, based on analysis of the single ascending dose portion of the ongoing Phase 1 study.

10 May 2018

New case study shows CAR T therapy as viable option for AML patients

Chimeric Antigen Receptor T-cell therapy, also known as CAR T therapy, was named the biggest research breakthrough of 2017 by the American Society of Clinical Oncology. The personal gene therapy utilizes a patient's own immune cells to fight cancer.

9 May 2018

New findings point to potential therapeutic avenues for leukemia

Scientists have known for decades that the Hox family of transcription factors are key regulators in the formation of blood cells and the development of leukemia.

9 May 2018

Moving beyond traditional 'magic bullet' approach for discovering new drugs

It's time to move beyond the traditional 'magic bullet' approach for discovering new drugs and start leveraging the full complexity of Mother Nature, say Vanderbilt Professor of Chemistry Brian Bachmann and Assistant Professor of Cell and Developmental Biology Jonathan Irish.

3 May 2018

Researchers identify novel pathway in development of AML with poor prognosis

Acute myeloid leukemia is a cancer of the blood and bone marrow that comprises 1% of all new cancer cases and almost 2% of cancer deaths in the U.S. The five-year survival rate for the disease is less than 20%.

24 Apr 2018

Experts propose new solutions to increase benefit, affordability of targeted cancer medicines

Spending on cancer drugs in the United States has nearly doubled in the past five years and continues to grow, imposing substantial financial burden on patients with cancer.

18 Apr 2018

Experimental peptide drug shows promise against acute myeloid leukemia

In a study published online today in Science Translational Medicine, Albert Einstein College of Medicine researchers report that an experimental peptide drug shows promise against the often-lethal cancer acute myeloid leukemia and describe how the drug works at the molecular level.

11 Apr 2018

New class of drug holds potential to help patients with treatment-resistant cancers

Researchers have discovered a new class of drug that has the potential to help cancer patients who no longer respond to existing therapies.

10 Apr 2018

Study finds link between industry payments and prescription practices for two cancer types

Physicians who received payment from pharmaceutical companies for meals, talks and travel were more likely to prescribe those companies' drugs for two cancer types, a University of North Carolina Lineberger Comprehensive Cancer Center-led study has found.

9 Apr 2018

Researchers probe RNA epigenetics and chromatin structures to predict drug resistance in leukemia

Drug resistance is a major obstacle to effective treatment for patients with cancer and leukemia. Epigenetic modifying drugs have been proven effective for some patients with hematologic malignancies, such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).

23 Mar 2018

Researchers discover key inner control mechanism of cell's 'smart glue'

Researchers at St. Jude Children's Research Hospital have discovered that a protein critical to a process called liquid-liquid phase separation within the cell undergoes internal changes in conformation that are key to its function.

26 Feb 2018

New NK cell-based immunotherapy effective against several types of leukemia

Researchers at Karolinska Institutet in Sweden have explored NK cell-based immunotherapy on patients with treatment-resistant leukemia. The study, which is published in the scientific journal Clinical Cancer Research, shows that the new therapy is effective against several types of leukemia.

15 Feb 2018

Researchers solve crystal structure for enzyme that plays key role in DNA methylation

A research team led by a biochemist at the University of California, Riverside has solved the crystal structure for an enzyme that plays a key role in DNA methylation, the process by which methyl groups are added to the DNA molecule.

7 Feb 2018

Modular gene enhancers may be suitable target in treatment of blood cancer

Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer.

18 Jan 2018

FDA grants approval for first drug to treat inherited breast cancer

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a "BRCA" gene mutation.

15 Jan 2018

U.S. FDA approves first drug for patients with germline BRCA-mutated metastatic breast cancer

AstraZeneca and Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved LYNPARZA (olaparib) for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.

12 Jan 2018

Leukemia patients currently ineligible for targeted therapy may benefit from new drugs

Patients with an aggressive form of leukemia, currently ineligible for any type of targeted therapy, may in fact benefit from some of these new drugs, according to new research by Queen Mary University of London.

9 Jan 2018

Novartis announces FDA approval of its first and only CML therapy with TFR data in product label

Novartis announced today that the US Food and Drug Administration (FDA) approved the inclusion of Treatment-free Remission (TFR) data in the Tasigna® (nilotinib) US product label.

26 Dec 2017

FDA researchers find underrepresentation of adults aged 75 years and older in blood cancer clinical trials

In the first comprehensive analysis of clinical trial enrollment among older adults with blood cancers, researchers from the U.S. Food and Drug Administration found significant gaps in participation among those aged 75 and older when considered against the incidence of these malignancies in this age group, according to research being presented today during the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta.

12 Dec 2017